Galapagos NV
glpg.comWhat Do They Do?
Develops potential medicines for patients with serious diseases and seeks to build its pipeline through business-development deals, with programs in immunology and oncology.
20-F for FY2025, filed Mar 26, 2026We are a biotechnology company built to bring meaningful medicines to patients with serious diseases. We combine world-class deal making…View ↗
As of December 31, 2025, our clinical pipeline included 1) GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE; 2)…View ↗
On October 21, 2025, we announced our intention to wind down our cell therapy activities and to pursue new transformational business…View ↗
Who Are Their Customers?
Collaboration partners license its intellectual property and may fund research work; Jyseleca product sales went to wholesalers and hospitals, and the company supplies inventory to Alfasigma.
20-F for FY2025, filed Mar 26, 2026In our agreements with customers we are mainly transferring licenses on our IP and in some cases this is combined with access rights and/or…View ↗
Collaboration and license agreements may include reimbursement or cost sharing for R&D services: such as outsourcing costs and payment for…View ↗
After completion of the sale of the Jyseleca® business we started to recognize sales of Jyseleca® inventories to Alfasigma as supply…View ↗
Product net sales is the net amount of revenue recognized resulting from transferring control over our products to our customer (for…View ↗
How Are They Changing?
Commercial rights transfer
Earlier, the company commercialized Jyseleca in Europe itself and through Sobi; the latest report says the Jyseleca business was transferred to Alfasigma, which took over its commercial and development activities.
20-F for FY2022, filed Mar 23, 2023 20-F for FY2025, filed Mar 26, 2026In 2021, we took full ownership of the manufacturing and commercialization of Jyseleca® in Europe and became the Marketing Authorization…View ↗
On October 30, 2023, we signed a letter of intent contemplating a transfer of the Jyseleca® business to Alfasigma S.p.A., or Alfasigma. The…View ↗
Pipeline strategy
The earlier report described a fully integrated business that discovered, developed, and commercialized medicines; the latest describes a strategy centered on identifying, acquiring, and advancing programs through business-development transactions.
20-F for FY2022, filed Mar 23, 2023We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are…View ↗
Cell therapy exit
The earlier report included CAR-T candidates in its clinical pipeline; the latest report says cell therapy programs are being wound down, leaving a non-cell therapy candidate in the pipeline.
20-F for FY2022, filed Mar 23, 2023 20-F for FY2025, filed Mar 26, 2026Our differentiated clinical pipeline includes: 1) preferential JAK1 inhibitor filgotinib, which is on the market in Europe and Japan, and…View ↗
Who Do They Compete With?
Competes with GSK, AstraZeneca, BMS, Abbvie, Idorsia, Viatris, Octapharma, Pfizer, and Argenx
20-F for FY2025, filed Mar 26, 2026For example, GLPG3667 faces significant competition in both the fields of DM and SLE. In the field of SLE, corticosteroids, antimalarials…View ↗
Loading...
